OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016

BOTHELL, Wash. and VANCOUVER, British Columbia, April 28, 2016 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016. Company management will host a conference call and live webcast at 4:30 p.m. Eastern Time to provide an overview of financial results, clinical development programs and a general corporate update.

To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing [phone] (U.S. & Canada) or [phone] (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account:  https://twitter.com/OncoGenex_IR.

SOURCE OncoGenex Pharmaceuticals, Inc.

Investor Relations: Jim DeNike, [email protected], 425-686-1514, http://www.OncoGenex.com